Kura Oncology (KURA) Stock Forecast, Price Target & Predictions
KURA Stock Forecast
Kura Oncology stock forecast is as follows: an average price target of $26.00 (represents a 63.42% upside from KURA’s last price of $15.91) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
KURA Price Target
The average price target for Kura Oncology (KURA) is $26.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $32.00 to $19.00. This represents a potential 63.42% upside from KURA's last price of $15.91.
KURA Analyst Ratings
According to 4 Wall Street analysts, Kura Oncology's rating consensus is 'Buy'. The analyst rating breakdown for KURA stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Kura Oncology Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 24, 2024 | David Dai | UBS | $27.00 | $17.02 | 58.64% | 69.70% |
| Oct 14, 2024 | Bradley Canino | Stifel Nicolaus | $19.00 | $18.58 | 2.26% | 19.42% |
| Jun 25, 2024 | Joseph Pantginis | H.C. Wainwright | $32.00 | $21.08 | 51.80% | 101.13% |
| May 23, 2024 | Bradley Canino | Stifel Nicolaus | $28.00 | $21.43 | 30.66% | 75.99% |
| Dec 22, 2023 | Mara Goldstein | Mizuho Securities | $26.00 | $13.81 | 88.27% | 63.42% |
The latest Kura Oncology stock forecast, released on Oct 24, 2024 by David Dai from UBS, set a price target of $27.00, which represents a 58.64% increase from the stock price at the time of the forecast ($17.02), and a 69.70% increase from KURA last price ($15.91).
Kura Oncology Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 5 |
| Avg Price Target | $27.00 | $23.00 | $26.40 |
| Last Closing Price | $15.91 | $15.91 | $15.91 |
| Upside/Downside | 69.70% | 44.56% | 65.93% |
In the current month, the average price target of Kura Oncology stock is $27.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 69.70% increase as opposed to Kura Oncology's last price of $15.91. This month's average price target is up 17.39% compared to last quarter, and up 2.27% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 24, 2024 | UBS | - | Buy | Initialise |
| Jun 25, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Feb 25, 2022 | Credit Suisse | Outperform | Outperform | Hold |
| Feb 25, 2022 | SVB Leerink | Outperform | Outperform | Hold |
Kura Oncology's last stock rating was published by UBS on Oct 24, 2024. The company Initialise its KURA rating from "null" to "Buy".
Kura Oncology Financial Forecast
Kura Oncology Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | $4.86M | - | - | - | - | - | - |
| High Forecast | $4.86M | - | - | - | - | - | - |
| Low Forecast | $4.86M | - | - | - | - | - | - |
| # Analysts | 1 | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Kura Oncology's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. KURA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Kura Oncology EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict KURA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Kura Oncology's previous annual EBITDA (undefined) of $NaN.
Kura Oncology Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-59.67M | $-64.05M | $-61.37M | $-59.20M | $-57.51M | $-54.44M | $-54.24M |
| High Forecast | $-59.67M | $-64.05M | $-61.37M | $-54.64M | $-46.01M | $-54.44M | $-54.24M |
| Low Forecast | $-59.67M | $-64.05M | $-61.37M | $-63.75M | $-66.36M | $-54.44M | $-54.24M |
| Surprise % | - | - | - | - | - | - | - |
Kura Oncology's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. KURA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Kura Oncology SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Kura Oncology's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to KURA last annual SG&A of $NaN (undefined).
Kura Oncology EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.69 | $-0.74 | $-0.71 | $-0.68 | $-0.66 | $-0.63 | $-0.63 |
| High Forecast | $-0.69 | $-0.74 | $-0.71 | $-0.63 | $-0.53 | $-0.63 | $-0.63 |
| Low Forecast | $-0.69 | $-0.74 | $-0.71 | $-0.73 | $-0.76 | $-0.63 | $-0.63 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Kura Oncology's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to KURA previous annual EPS of $NaN (undefined).
Kura Oncology Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ZNTL | Zentalis Pharmaceuticals | $3.13 | $21.86 | 598.40% | Buy |
| INZY | Inozyme Pharma | $2.79 | $14.67 | 425.81% | Buy |
| LRMR | Larimar Therapeutics | $6.08 | $20.33 | 234.38% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.62 | $38.80 | 184.88% | Buy |
| KALV | KalVista Pharmaceuticals | $8.96 | $22.67 | 153.01% | Buy |
| ERAS | Erasca | $2.64 | $6.50 | 146.21% | Buy |
| REPL | Replimune Group | $11.23 | $24.20 | 115.49% | Buy |
| SNDX | Syndax Pharmaceuticals | $15.95 | $34.30 | 115.05% | Buy |
| COGT | Cogent Biosciences | $9.08 | $18.83 | 107.38% | Buy |
| VRDN | Viridian Therapeutics | $19.79 | $37.92 | 91.61% | Buy |
| MRUS | Merus | $42.93 | $77.13 | 79.66% | Buy |
| DSGN | Design Therapeutics | $5.48 | $9.67 | 76.46% | Buy |
| KNSA | Kiniksa Pharmaceuticals | $21.21 | $36.33 | 71.29% | Buy |
| KURA | Kura Oncology | $15.91 | $26.00 | 63.42% | Buy |
| CRNX | Crinetics Pharmaceuticals | $56.07 | $70.14 | 25.09% | Buy |
| PTGX | Protagonist Therapeutics | $40.65 | $50.00 | 23.00% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |